News

Chronic pain among adolescents and young adults with sickle cell disease (SCD) is associated with more functional disability — meaning patients are less able to independently perform daily activities such as bathing, dressing, eating, or working — as well as lower health-related quality of life, according to a new…

A neurodevelopmental screening tool may identify toddlers and preschool children with sickle cell disease (SCD) who are at risk for long-term academic difficulties, a study shows. The tool, called the Ages and Stages Questionnaire (ASQ), is based on parent-reported acquisition of developmental milestones across fine and gross motor…

Researchers from the University of Illinois Chicago (UIC) have received $3.78 million in federal funding to evaluate whether a diabetes medication can slow kidney damage in people with sickle cell disease (SCD). People with SCD face a higher likelihood of developing chronic kidney disease and often lose kidney…

Memantine, an oral medication that’s been used for decades to help treat Alzheimer’s disease, is generally tolerated well by people with sickle cell disease (SCD) and may help prevent painful disease crises, especially in children. Those are the findings of a small, one-year study in Israel that tested…

The breakdown of red blood cells — a defining feature of sickle cell disease (SCD) — may contribute to the cognitive problems many people with the condition experience, a study suggested. Researchers found that the breakdown of red blood cells, known as hemolysis, releases heme into the bloodstream, which…

Higher levels of fetal hemoglobin (HbF) seem to protect people with sickle cell disease (SCD) by reducing the risk of lung problems, such as pulmonary hypertension, and delaying bone damage, at least in men, according to a study from a single center in Georgia. The study, “The Role…

In a mouse study, blood stem cells from sickle cell disease (SCD) patients modified with CRISPR/Cas9 gene editing showed reduced long-term contribution compared with cells treated using other gene-based approaches. “While all methods showed therapeutic potential, base editing and [gene therapy] provided superior outcomes over CRISPR-Cas9-mediated editing in a…

Emmaus Life Sciences has entered into an agreement to sell the North American rights to Endari (oral L-glutamine), its oral treatment to prevent acute complications related to sickle cell disease (SCD), to Neoimmunetech. Under the agreement, Neoimmunetech will receive an exclusive license to all rights for marketing,…

Hydroxyurea, blood transfusions, and donor blood stem cell transplants can significantly lower the risk of stroke in children and adolescents with sickle cell anemia (SCA), the most common and severe form of sickle cell disease. That’s according to a systematic review and meta-analysis of 40 studies that also highlighted…